NASDAQ:VACC

Vaccitech - VACC Stock Forecast, Price & News

$2.23

-0.24 (-9.72%)

(As of 03/28/2023 05:13 PM ET)

Add

Compare

Today's Range: $2.16
▼
$2.31
50-Day Range: $2.16
▼
$3.15
52-Week Range: $2.02
▼
$7.45

Volume: 204,269 shs
Average Volume: 66,401 shs
Market Capitalization: $83.18 million

P/E Ratio: 14.87
Dividend Yield: N/A
Price Target: $12.67

Institutional Ownership

Vaccitech MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 468.0% Upside
$12.67 Price Target
Short Interest: Healthy
0.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.42
Based on 21 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.52) to ($3.05) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

170th out of 1,002 stocks

Pharmaceutical Preparations Industry

70th out of 488 stocks

3.5

Analyst's Opinion

Consensus Rating
Vaccitech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.67, Vaccitech has a forecasted upside of 468.0% from its current price of $2.23.
Amount of Analyst Coverage
Vaccitech has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.04% of the float of Vaccitech has been sold short.
Short Interest Ratio / Days to Cover
Vaccitech has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vaccitech has recently decreased by 16.57%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Vaccitech does not currently pay a dividend.
Dividend Growth
Vaccitech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VACC.

3.0

News and Social Media Coverage

News Sentiment
Vaccitech has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 21 news articles for Vaccitech this week, compared to 1 article on an average week.
Search Interest
20 people have searched for VACC on MarketBeat in the last 30 days.
MarketBeat Follows
4 people have added Vaccitech to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vaccitech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.00% of the stock of Vaccitech is held by insiders.
Percentage Held by Institutions
Only 27.07% of the stock of Vaccitech is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Vaccitech are expected to decrease in the coming year, from ($2.52) to ($3.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vaccitech is 14.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.83.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vaccitech is 14.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 93.00.
Price to Book Value per Share Ratio
Vaccitech has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vaccitech (NASDAQ:VACC) Stock

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Receive VACC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter.

VACC Stock News Headlines

March 28, 2023 | finanznachrichten.de

Vaccitech plc: Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

March 28, 2023 | finance.yahoo.com

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

March 28, 2023 | Tradewins (Ad)

Modern Day Options Trading For Beginners!

These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market.

March 28, 2023 | americanbankingnews.com

Barclays Trims Vaccitech (NASDAQ:VACC) Target Price to $7.00

March 27, 2023 | msn.com

Vaccitech Earnings Perspective: Return On Capital Employed

March 27, 2023 | benzinga.com

UK leadership in health, food and sustainability prompts Milltrust to launch follow-on university venture fund.

March 27, 2023 | msn.com

New $150m fund set to invest in ‘high-impact’ firms across food and healthcare

March 25, 2023 | americanbankingnews.com

Vaccitech plc (NASDAQ:VACC) to Post FY2022 Earnings of $0.26 Per Share, HC Wainwright Forecasts

March 28, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

March 24, 2023 | finanznachrichten.de

Vaccitech plc: Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

March 24, 2023 | msn.com

Banking Sector Worries Weigh on American Depositary Receipts of European Equities

March 24, 2023 | benzinga.com

Vaccitech shares are trading higher after the company reported better-than-expected FY22 sales results.

March 24, 2023 | finance.yahoo.com

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

March 22, 2023 | marketwatch.com

Influenza Vaccines Market Share and Forecast till 2031

March 21, 2023 | americanbankingnews.com

Vaccitech (NASDAQ:VACC) Stock Rating Reaffirmed by HC Wainwright

March 20, 2023 | finance.yahoo.com

Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions

March 20, 2023 | finance.yahoo.com

Vaccitech Says Prime-boost Vaccine Study Data In Women With Low-grade HPV Lesions Is 'Promising Step In Right Direction'

March 16, 2023 | finance.yahoo.com

Owning 39% shares,institutional owners seem interested in Vaccitech plc (NASDAQ:VACC),

March 13, 2023 | marketwatch.com

Prostate Cancer Vaccines Market to Grow Exponentially Due to Rising Demand

March 6, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Esperion (ESPR) and Vaccitech Plc (VACC)

February 2, 2023 | marketwatch.com

Prostate Cancer Vaccines Market : Research Report Analysis by Competitors, Sales, Revenue and Industry Size 2023 To 2028

January 30, 2023 | msn.com

Vaccitech appoints new Chief Scientific Officer

January 30, 2023 | finance.yahoo.com

Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer

January 30, 2023 | ft.com

The growing tensions around spinouts at British universities

January 22, 2023 | sg.finance.yahoo.com

Vaccitech plc (VACC) stock historical prices & data – Yahoo Finance

January 13, 2023 | finance.yahoo.com

Vaccitech (NASDAQ:VACC) adds US$10m to market cap in the past 7 days, though investors from a year ago are still down 73%

January 10, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Renalytix AI (RNLX)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VACC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter.

VACC Company Calendar

Last Earnings: 11/12/2021
Today: 3/28/2023
Next Earnings (Estimated): 5/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VACC
CUSIP: N/A
CIK: 1828185
Web: www.vaccitech.co.uk
Phone: 44-0-18-6581-8808
Fax: N/A
Employees: 72
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.67
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +412.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.15
Trailing P/E Ratio: 16.47
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $5.34 million
Net Margins: 11.95%
Pretax Margin: 27.77%
Return on Equity: 2.13%
Return on Assets: 1.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.58
Quick Ratio: 15.58

Sales & Book Value

Annual Sales: $44.70 million
Price / Sales: 2.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.24 per share
Price / Book: 0.34

Miscellaneous

Outstanding Shares: 37,300,000
Free Float: 34,686,000
Market Cap: $92.13 million
Optionable: Not Optionable
Beta: 0.21

Key Executives

Mr. William J. Enright MBA (Age 59)
CEO & Director
Comp: $754.28k

Dr. Margaret Marshall M.D. (Age 65)
Chief Medical Officer
Comp: $547.97k

Ms. Sarah Gilbert
Co-Founder

Mr. Adrian Hill Ph.D.
Co-Founder & Scientific Advisor

Ms. Gemma Brown
Chief Financial Officer

Mr. Chris Ellis (Age 62)
Chief Operating Officer

Dr. Thomas George Evans M.D. (Age 67)
Chief Scientific Officer

Mr. Graham Griffiths (Age 43)
Chief Bus. Officer

Ms. Elizabeth Eagling-Vose M.B.A.
Head of Clinical Operations

Bernie McDonald
Head of IP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VACC Stock - Frequently Asked Questions

Should I buy or sell Vaccitech stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VACC shares.
View VACC analyst ratings or view top-rated stocks.
What is Vaccitech's stock price forecast for 2023?: 2 brokerages have issued twelve-month price targets for Vaccitech's shares. Their VACC share price forecasts range from $7.00 to $16.00. On average, they predict the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 412.8% from the stock's current price.
View analysts price targets for VACC or view top-rated stocks among Wall Street analysts.
How have VACC shares performed in 2023?: Vaccitech's stock was trading at $2.35 at the beginning of 2023. Since then, VACC stock has increased by 5.1% and is now trading at $2.47.
View the best growth stocks for 2023 here.
Are investors shorting Vaccitech?: Vaccitech saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 14,600 shares, a decrease of 16.6% from the February 28th total of 17,500 shares. Based on an average trading volume of 68,200 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are short sold.
View Vaccitech's Short Interest.
When is Vaccitech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our VACC earnings forecast.
How were Vaccitech's earnings last quarter?: Vaccitech plc (NASDAQ:VACC) announced its earnings results on Friday, November, 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.25. The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $1.65 million. Vaccitech had a net margin of 11.95% and a trailing twelve-month return on equity of 2.13%.

When did Vaccitech IPO?: (VACC) raised $110 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.
What is Vaccitech's stock symbol?: Vaccitech trades on the NASDAQ under the ticker symbol "VACC."
Who are Vaccitech's major shareholders?: Vaccitech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baird Financial Group Inc. (0.25%) and Millennium Management LLC (0.11%). Insiders that own company stock include Christopher Ellis, Graham Griffiths, Joseph Scheeren, Karen A Dawes, M&G Investment Management Ltd, Robin Wright and Sciences Innovation Plc Oxford.
View institutional ownership trends.
How do I buy shares of Vaccitech?: Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vaccitech's stock price today?: One share of VACC stock can currently be purchased for approximately $2.47.
How much money does Vaccitech make?: Vaccitech (NASDAQ:VACC) has a market capitalization of $92.13 million and generates $44.70 million in revenue each year. The company earns $5.34 million in net income (profit) each year or $0.15 on an earnings per share basis.
How can I contact Vaccitech?: Vaccitech's mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The official website for the company is www.vaccitech.co.uk. The company can be reached via phone at 44-0-18-6581-8808 or via email at ir@vaccitech.co.uk..

This page (NASDAQ:VACC) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vaccitech - VACC Stock Forecast, Price & News

Vaccitech MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Vaccitech (NASDAQ:VACC) Stock

VACC Stock News Headlines

VACC Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VACC Stock - Frequently Asked Questions

Overall MarketRank^™